Dianthus Therapeutics CFO Sells $9.5 Million in Stock

April 06, 2026 — 03:47 pm EDT Written byPamela KockforThe Motley Fool-> 114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026. The transaction represented 100% of Savitz's direct common stock holdings, reducing direct ownership of this class to zero. This activity involved an exercise of options for common stock, immediately sold in the open market; no indirect or trust entities participated. Savitz retains Stock Option (Right to Buy): 90,399 shares (direct), which can be converted to common stock. Ryan Savitz, executive vice president, chief financi